New anticoagulants.
Review published in American heart journal (2001)
Abstract
BACKGROUND: Heparin and coumarins have been in clinical use for more than 50 years. Low-molecular-weight heparins (including a heparinoid), developed 25 years ago, have been used clinically for more than a decade. METHODS: In the last 10 years, several new anticoagulants that target almost every step in the coagulation pathway have been developed. Of these, 3 direct thrombin inhibitors (hirudin, bivalirudin, and argatroban) are approved for clinical use. Four other anticoagulants (activated protein C, tissue factor pathway inhibitor, synthetic pentasaccharide, and the oral thrombin inhibitor H376/95) are being evaluated or have completed evaluation in phase III studies; various other compounds are in phase II studies. RESULTS: The mechanism of action, sites of action, and potential clinical indications of these new anticoagulants are reviewed. CONCLUSIONS: To compete effectively, the new oral anticoagulants currently under development will have to be at least as effective and safe as coumarins, oral thrombin, or Factor Xa inhibitors and require less monitoring.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Heparin and coumarins have been in clinical use for more than 50 years. Low-molecular-weight heparins (including a heparinoid), developed 25 years ago, have been used clinically for more than a decade.
Por qué esto importa para la hirudoterapia
Esta revisión examina el desarrollo de nuevos fármacos anticoagulantes dirigidos a casi cada una de las etapas de la vía de la coagulación, detallando sus mecanismos de acción, sitios de acción y posibles indicaciones clínicas. El resumen identifica la hirudina —junto con bivalirudina y argatrobán— como uno de tres inhibidores directos de la trombina ya aprobados para uso clínico. Para el dominio de la ASH, la mención explícita de la hirudina como anticoagulante clínico establecido confirma su lugar reconocido dentro de la farmacopea anticoagulante más amplia. Sin embargo, el alcance del artículo es extremadamente amplio, cubriendo diversos agentes farmacéuticos sistémicos, y el resumen no aborda la hirudoterapia, la aplicación de sanguijuelas vivas, el secretoma de la sanguijuela ni el origen biológico de la hirudina.
Citación
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026